Chicago Partners Investment Group LLC Has $392,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

Chicago Partners Investment Group LLC increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 24.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,628 shares of the medical instruments supplier’s stock after acquiring an additional 319 shares during the period. Chicago Partners Investment Group LLC’s holdings in Becton, Dickinson and Company were worth $392,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. WR Wealth Planners LLC raised its holdings in shares of Becton, Dickinson and Company by 1.4% during the second quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after acquiring an additional 42 shares during the period. Clear Creek Financial Management LLC raised its holdings in shares of Becton, Dickinson and Company by 5.1% during the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock worth $210,000 after acquiring an additional 44 shares during the period. Sound Income Strategies LLC raised its holdings in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares during the period. Central Pacific Bank Trust Division increased its stake in Becton, Dickinson and Company by 22.5% in the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 45 shares during the last quarter. Finally, Capital Advisors Ltd. LLC increased its stake in Becton, Dickinson and Company by 3.6% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 1,394 shares of the medical instruments supplier’s stock valued at $326,000 after buying an additional 48 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BDX. Raymond James lowered their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Evercore ISI lifted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus lifted their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price target for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $234.33 on Tuesday. The company has a market capitalization of $67.73 billion, a price-to-earnings ratio of 48.22, a PEG ratio of 1.75 and a beta of 0.43. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. The company has a 50-day simple moving average of $237.52 and a 200 day simple moving average of $235.10. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $259.92.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.